TY  - JOUR
AU  - Mauz-Körholz, Christine
AU  - Landman-Parker, Judith
AU  - Balwierz, Walentyna
AU  - Ammann, Roland A
AU  - Anderson, Richard A
AU  - Attarbaschi, Andische
AU  - Bartelt, Jörg M
AU  - Beishuizen, Auke
AU  - Boudjemaa, Sabah
AU  - Cepelova, Michaela
AU  - Claviez, Alexander
AU  - Daw, Stephen
AU  - Dieckmann, Karin
AU  - Fernández-Teijeiro, Ana
AU  - Fosså, Alexander
AU  - Gattenlöhner, Stefan
AU  - Georgi, Thomas
AU  - Hjalgrim, Lisa L
AU  - Hraskova, Andrea
AU  - Karlén, Jonas
AU  - Kluge, Regine
AU  - Kurch, Lars
AU  - Leblanc, Thiery
AU  - Mann, Georg
AU  - Montravers, Francoise
AU  - Pears, Jean
AU  - Pelz, Tanja
AU  - Rajić, Vladan
AU  - Ramsay, Alan D
AU  - Stoevesandt, Dietrich
AU  - Uyttebroeck, Anne
AU  - Vordermark, Dirk
AU  - Körholz, Dieter
AU  - Hasenclever, Dirk
AU  - Wallace, William Hamish
PY  - 2021
DO  - 10.1016/S1470-2045(21)00470-8
UR  - http://hdl.handle.net/10668/22554
T2  - The Lancet. Oncology
AB  - Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by...
LA  - en
KW  - Adolescent
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Child
KW  - Cyclophosphamide
KW  - Female
KW  - Follicle Stimulating Hormone
KW  - Hodgkin Disease
KW  - Humans
KW  - Male
KW  - Neoplasm Staging
KW  - Prednisone
KW  - Procarbazine
KW  - Vincristine
TI  - Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
TY  - research article
VL  - 23
ER  -